-
BeiGene and BeiZeAn are approved for new indications in the United States
Recently, BeiGene announced that the US Food and Drug Administration (FDA) has approved the use of BeiGene (Trastuzumab) in combination with platinum and fluorouracil chemotherapy for first-line trea ... -
BeiGene issues 100000 shares, with an increase of 0.007%
BeiGene (688235/06160/BGNE) announced on December 30 that as of December 29, 2024, the total number of issued shares of the company was 1.269 billion shares, an increase of 100000 shares or 0.007% co ... -
BeiGene NASDAQ stock code will be changed to 'ONC'
On December 24th, BeiGene announced that the stock code of its American Depositary Shares traded on NASDAQ will be changed from "BGNE" to "ONC", effective from January 2, 2025, to demonstrate the com ... -
BeiGene: NASDAQ stock code will be changed to 'ONC'
On December 23rd, BeiGene announced that it will change its NASDAQ stock code to "ONC" on January 2nd, 2025. The BeiGene CUSIP code remains unchanged. In addition, the company's stock code and securi ... -
Puyin International: downgraded BeiGene A-share rating to 'hold', maintaining target price of 181 yuan
Caixin News Agency, November 14th - Puyin International released a research report, maintaining the "buy" rating of BeiGene (688235) on US and Hong Kong stocks, and adjusting the target prices of US ... -
BeiGene executive Yin Min is suspected of smuggling and cooperating with the investigation
BeiGene executive Yin Min is suspected of smuggling and cooperating with the investigation. Yin Min, the Chief Commercial Officer of BeiGene Greater China, has been taken away by the Shenzhen anti sm ... -
A senior executive of BeiGene has been investigated, and insiders say that the reason for the investigation is unrelated to BeiGene
On October 25th, there were rumors in the market that Yin Min, the Chief Commercial Officer of BeiGene (BGNE. NS, 06160. HK, 688235. SH) in Greater China, was under investigation by regulatory author ... -
BeiGene executive Yin Min is under investigation after previously serving at AstraZeneca | News
Domestic innovative pharmaceutical companies have once again exposed a deep-water bomb. On October 25th, Yin Min, the Chief Commercial Officer of BeiGene Greater China, a leading domestic innovative ... -
BeiGene responds to AbbVie's lawsuit alleging theft of trade secrets: with the intention of obstructing the development process
Blue Whale News, September 12th (Reporter Tu Jun) Following the patent infringement lawsuit filed by AbbVie in June last year regarding its core product BTK inhibitor Baiyueze (Zebutinib Capsules), i ... -
BeiGene denies AbbVie's accusation of "stealing trade secrets": will launch a firm defense and development projects will not be interrupted as a result
On September 12th, the A-share price of BeiGene (SH688235, stock price 144.01 yuan, market value 198.44 billion yuan) fell sharply by 10.61%. On the afternoon of the 12th, BeiGene told the Daily Econ ... -
Domestic innovative drug leader faces another 'patent challenge': AbbVie accuses BTK degradation agent of infringement, causing BeiGene's stock price to suffer a setback
Multinational pharmaceutical company AbbVie has recently sued BeiGene again. According to market news, AbbVie accuses BeiGene of hiring a senior scientist who used to work at AbbVie and stealing trad ... -
AbbVie sues for infringement again, BeiGene denies allegations: this move is intended to prevent project development
Two companies in the field of hematological oncology, AbbVie and BeiGene, have once again taken legal action. Industry media Fierce Biotech recently reported that AbbVie has filed a lawsuit against B ... -
More than 40% reduction in losses in the first half of the year, but multiple peers have achieved profits. BeiGene is facing increasing peer pressure
In the first half of the year, BeiGene (688235.SH, stock price 145.48 yuan, market value 2002.31 billion yuan) has been the "leader" in China's new drug industry for more than 2 years, but has not ye ... -
Company Review | BeiGene has suffered continuous losses in the past 7 years, and its stock price is under pressure. Can the new CFO bring a turning point?
On August 7th, BeiGene (SH688235, stock price 140.88 yuan, market value 193.9 billion yuan) released its financial report for the first half of 2024, with a total operating revenue of 11.996 billion ... -
BeiGene: Chief Financial Officer Wang Aijun will resign on July 19th
According to AI News, on July 18th, BeiGene announced that its Chief Financial Officer, Wang Aijun, has recently submitted a resignation application to seek external development opportunities. He wil ... -
BeiGene: Net profit for 2023 is approximately -6.716 billion yuan
Baekje Shenzhou (SH 688235, closing price: 130.77 yuan) released its annual performance report on April 27, stating that its operating revenue in 2023 was approximately 17.423 billion yuan, an increa ... -
After a series of twists and turns, the core product of Baekje Shenzhou, Baekze An, has become the second domestically produced PD-1 approved in the United States
After nearly two years, the BeiGene PD-1 has finally knocked on the door of the US FDA. On March 15th, Baekje Shenzhou announced that the FDA has approved the Baekje Shenzhou PD-1 inhibitor tirelizum ... -
Baekje Shenzhou PD-1 has been approved by FDA as the second product in China after Junshi Biotechnology
Beijing, March 15th (Reporter Cao Qian, Intern Xie Xiaoxuan) Today, BeiGene announced that its PD-1 inhibitor, Tevimbra, has been approved by the FDA for the treatment of advanced or metastatic esoph ... -
BeiGene: The first indication approved for tirizizumab in the United States
On March 15th, Baekje announced that the US Food and Drug Administration (FDA) has approved tirizizumab (Chinese trade name: Baekzean®; English trade name: TEVIMBRA®) as a monotherapy for adu ... -
Baekje Shenzhou Baiyue Ze has received FDA accelerated approval for the treatment of recurrent or refractory follicular lymphoma
Recently, BeiGene announced that Baiyue Ze& Reg; Zebutinib has been granted accelerated approval by the US Food and Drug Administration (FDA) for use in combination with the anti-CD20 monoclonal anti ...